Specialty Pharma Journal Specialty, Precision & Technology
THOUSAND OAKS, Calif. and HOUSTON, May 31, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen’s early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies. The agreements combine Amgen therapies …
Tag Archives: University of Texas MD Anderson Cancer Center
June, 2018
September, 2017
-
27 September
MD Anderson and Pfizer Collaborate to Evaluate Immuno-Oncology Combinations in Blood Cancers and Solid Tumors
The University of Texas MD Anderson Cancer Center and Pfizer Inc. today announced that they have entered into a clinical collaboration to study novel combinations of three Pfizer investigational immuno-oncology therapies and other Pfizer agents in the treatment of various solid tumors and hematologic malignancies. “This alliance aims to define patients …
-
14 September
Daiichi Sankyo and MD Anderson Collaborate to Accelerate Development of Acute Myeloid Leukemia Therapies
HOUSTON and TOKYO and BASKING RIDGE, N.J., Sept. 14, 2017 /PRNewswire/ — The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced a multi-year collaboration focused on accelerating the development of novel therapies for acute myeloid leukemia (AML). The collaboration represents an …
March, 2016
-
30 March
Tesaro and MD Anderson Enter Immuno-Oncology Collaboration
WALTHAM, Mass. and HOUSTON, March 29, 2016 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, and the Institute for Applied Cancer Science at The University of Texas MD Anderson Cancer Center today announced an exclusive collaboration to discover and develop small molecule product candidates against undisclosed immuno-oncology targets. …